Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CEVEC Pharmaceuticals has entered into collaboration with Catalent Pharma Solutions for a joint cell line development service for pharma and biotech customers.
Subscribe to our email newsletter
The offering combines the benefits of CEVEC’s human cell line and CAP-technology with Catalent’s gene product expression (GPEx) technology to generate stable human cell lines in a much shorter time frame than traditional methods.
CEVEC MD and CCO Wolfgang Kintzel said they achieved yields exceeding 3 g/L for a complex protein produced in their human production cell lines in a very short time frame.
"The combined offering is a compelling value proposition for clients looking to outsource cell line development and potential downstream cGMP upscaling while looking for the quality using a human cell line," Kintzel said.
Catalent Development & Clinical Services president Scott Houlton said this collaboration with CEVEC will offer biotech companies developing recombinant proteins and antibodies the advantage of two technologies in one system, enabling them to get a clone candidate in less than 5 months and reducing their time to clinic.
"The GPEx technology has been used to express more than 380 different molecules and our integrated development and manufacturing services allow us to take our customers through their clinical trials," Houlton said.